Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6UXX9
UPID:
RSPO2_HUMAN
Alternative names:
Roof plate-specific spondin-2
Alternative UPACC:
Q6UXX9; B3KVP0; Q4G0U4; Q8N6X6
Background:
R-spondin-2, also known as Roof plate-specific spondin-2, is a pivotal activator of the canonical Wnt signaling pathway. It functions by serving as a ligand for LGR4-6 receptors, facilitating the association with phosphorylated LRP6 and frizzled receptors activated by Wnt, thereby enhancing gene expression. Crucially, it plays a significant role in limb development by amplifying Wnt signaling, potentially acting as a direct antagonist to RNF43 and ZNRF3.
Therapeutic significance:
R-spondin-2's involvement in diseases such as Tetraamelia syndrome 2 and Humerofemoral hypoplasia highlights its critical role in limb formation and development. Understanding the role of R-spondin-2 could open doors to potential therapeutic strategies for these congenital disorders, offering hope for targeted treatments.